Education
About Us
Working with TipRanks
Follow Us
Autolus Therapeutics Plc (AUTL)
NASDAQ:AUTL
AUTL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.52 - $5.84
Previous CloseN/A
Volume359.61K
Average Volume (3M)1.25M
Market Cap
$412.48M
Enterprise Value$608.52M
Total Cash (Recent Filing)$120.67M
Total Debt (Recent Filing)$258.00K
Price to Earnings (P/E)―
Beta2.33
Next Earnings
May 01, 2025EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.87
Shares Outstanding266,128,900
10 Day Avg. Volume1,285,588
30 Day Avg. Volume1,246,749
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)44.29
Price to Cash Flow (P/CF)-1.50
P/FCF Ratio0.00
Enterprise Value/Market Cap1.48
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-480.29
Enterprise Value/Ebitda-3.01
Forecast
1Y Price Target
$8.67Price Target Upside514.89% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Autolus Therapeutics News
PremiumCompany Announcements
Autolus Therapeutics: Positive Momentum Amid Financial Challenges
PremiumCompany Announcements
Autolus Therapeutics Reports Strong 2024 Results
---
Bulls Say, Bears Say
Bulls Say
Market ExpansionAutolus has been focused on activation of the initial wave of treatment centers, with 33 centers authorized, ahead of company guidance.
Product DifferentiationAUTL noted Aucatzyl's better safety and a better business case, allowing centers to treat more patients and hence greater profit.
Regulatory ApprovalsMAA review is ongoing in the EU and U.K. with potential approvals expected.
Bears Say
Option ExerciseBNTX did not exercise its option for AUTO1/22 in pediatric B-ALL.
Sales ProjectionsManagement did not provide guidance on sales or patient numbers due to difficulties in projecting these figures.
Valuation ConcernsWe find AUTL significantly undervalued with little or no value given to obe-cel in r/r ALL.
---
Ownership Overview
― Insiders
14.07% Mutual Funds
37.46% Other Institutional Investors
47.61% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AUTL FAQ
What was Autolus Therapeutics Plc’s price range in the past 12 months?
Autolus Therapeutics Plc lowest stock price was $1.52 and its highest was $5.84 in the past 12 months.
What is Autolus Therapeutics Plc’s market cap?
Autolus Therapeutics Plc’s market cap is $412.48M.
When is Autolus Therapeutics Plc’s upcoming earnings report date?
Autolus Therapeutics Plc’s upcoming earnings report date is May 01, 2025 which is in 29 days.
How were Autolus Therapeutics Plc’s earnings last quarter?
Autolus Therapeutics Plc released its earnings results on Mar 20, 2025. The company reported -$0.09 earnings per share for the quarter, beating the consensus estimate of -$0.206 by $0.116.
Is Autolus Therapeutics Plc overvalued?
According to Wall Street analysts Autolus Therapeutics Plc’s price is currently Undervalued.
Does Autolus Therapeutics Plc pay dividends?
Autolus Therapeutics Plc does not currently pay dividends.
What is Autolus Therapeutics Plc’s EPS estimate?
Autolus Therapeutics Plc’s EPS estimate is -0.25.
How many shares outstanding does Autolus Therapeutics Plc have?
Autolus Therapeutics Plc has 266,128,900 shares outstanding.
What happened to Autolus Therapeutics Plc’s price movement after its last earnings report?
Autolus Therapeutics Plc reported an EPS of -$0.09 in its last earnings report, beating expectations of -$0.206. Following the earnings report the stock price went down -13.402%.
Which hedge fund is a major shareholder of Autolus Therapeutics Plc?
Currently, no hedge funds are holding shares in AUTL
---
Autolus Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.67 (514.89% Upside)
$8.67 (514.89% Upside)
Blogger Sentiment
Bullish
AUTL Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 3.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 6.2%
Last 30 Days ▼ 6.2%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-75.70%
12-Months-Change
Fundamentals
Return on Equity
-81.91%
Trailing 12-Months
Asset Growth
108.51%
Trailing 12-Months
Company Description
Autolus Therapeutics Plc
Autolus Therapeutics (AUTL) is a biopharmaceutical company that operates in the biotechnology sector, focusing on the development and commercialization of next-generation, programmed T cell therapies for the treatment of cancer. The company's core products are designed to reprogram the body's immune system to recognize and eliminate cancer cells, leveraging its proprietary technology to create highly targeted therapies.
---
AUTL Company Deck
---
AUTL Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a generally positive sentiment, highlighting the successful U.S. launch of AUCATZYL, strong financial backing, and promising clinical data. However, financial challenges remain with increased operating and net losses, as well as high R&D expenditures.Read More>---
AUTL Stock 12 Month Forecast
Average Price Target
$8.67
▲(514.89% Upside)
Technical Analysis
Bluebird Bio
―
Agios Pharma
―
Fate Therapeutics
―
Cara Therapeutics
―
Adaptimmune Therapeutics
―
Best Analysts Covering AUTL
1 Year
---